Nova Eye Medical (Nova Eye Medical) LT-Debt-to-Total-Asset : 0.02 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Nova Eye Medical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nova Eye Medical's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.02.

Nova Eye Medical's long-term debt to total assets ratio declined from Dec. 2022 (0.04) to Dec. 2023 (0.02). It may suggest that Nova Eye Medical is progressively becoming less dependent on debt to grow their business.

Nova Eye Medical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Nova Eye Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Eye Medical LT-Debt-to-Total-Asset Chart

Nova Eye Medical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.04

0.03

Nova Eye Medical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.04	0.04	0.03	0.02

Nova Eye Medical LT-Debt-to-Total-Asset Calculation

Nova Eye Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )	/	Total Assets (A: Jun. 2023 )
	=	0.599	/	20.374
	=	0.03

Nova Eye Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0.374	/	15.979
	=	0.02

Nova Eye Medical (OTCPK:ELXMF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nova Eye Medical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Nova Eye Medical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Eye Medical (Nova Eye Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nova Eye Medical Ltd (OTCPK:ELXMF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

EYE:Australia

Address

107 Rundle Street, Kent Town, Adelaide, SA, AUS, 5067

Website

https://www.nova-eye.com

Nova Eye Medical Ltd is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The company's operating segment include AlphaRET and Glaucoma Surgical Devices, it generates maximum revenue from Glaucoma Surgical Devices. Geographically, it derives a majority of revenue from the United States of America.

Nova Eye Medical (Nova Eye Medical) Headlines

From GuruFocus

ABK Biomedical Appoints Michael J. Mangano as President and Chief Executive Officer

By PRNewswire PRNewswire • 07-30-2018

Nova Eye Medical Announces U.S. Market Clearance of the iTrack� Advance Canaloplasty Device

By Business Wire Business Wire • 04-12-2023